Dr. John Cush RheumNow
3 years 9 months ago
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/nuq8Ioralk https://t.co/djwlVsIk3b
Dr. John Cush RheumNow
3 years 9 months ago
#ACR22 - SpA Part2
-Comorbidities in Ankylosing Spondylitis
-Early Diagnosis of AxSpA
-Fertility issues in SpA
-Gender in AxSpa
-Inadequate Dosing of HCQ Leads to Hospitalizations in SLE
-JAK inhibitors in RD
-Opioid use in PsA and SpA
https://t.co/1xJzSmekR2 https://t.co/kxpLGi8Ky4
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways.
Dr. John Cush RheumNow
3 years 9 months ago
#ACR22- SpA Part1
-AI Future of Sacroiliitis Assessment AI in Detecting Sacroiliitis
-AxSpA: gender differences
-Can we alter neonatal gut microbiome to prevent SpA?
-Comorbidities in AxSpA
-Do Disease Activity Measures Really Capture AS in Women?
https://t.co/sFIZz7pKSF https://t.co/CAh5TZ4FEX
Dr. John Cush RheumNow
3 years 9 months ago
PreRA to Treat or Not!
Dr. Janet Pope ( @Janetbirdope ) weighs in. #ACR22
https://t.co/778jWLizeW https://t.co/ZHIQTuYyyg
Dr. John Cush RheumNow
3 years 9 months ago
Prescribing Methotrexate in Post-Roe Era
Dr. Cassy Sims ( @DrCassySims) reports live from #ACR22.
L09: Impact on Access to Methotrexate in the Post-Roe Era
https://t.co/GwgSqBj5EX https://t.co/WzFGnJyIf3
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
How women can reduce the risk of hip fracture?
Dr. John Cush RheumNow
3 years 9 months ago
Is exercise the missing medicine in lupus?
Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical Inactivity is Associated with Increased Expression of T cell inflammatory genes in Systemic Lupus.”
https://t.co/LomZ8U8pzj https://t.co/PEZHypeasB
Idiopathic inflammatory myopathy (IIM) is associated with increased risk of lung, ovarian, colorectal, lymphoma, breast, and naso-pharyngeal cancers, often within three years of disease onset. At ACR22, plenary abstract 0002, Oldroyd, et al, reviewed the 18 recommendations provided by the International Myositis Assessment and Clinical Studies Group (IMACS) steering committee.
Dr. John Cush RheumNow
3 years 9 months ago
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at #ACR22 Convergence.
https://t.co/nrsH7yB7wu https://t.co/TngS4Kk6YK
